Abstract 4528
Background
Triple negative breast cancer carries a poor prognosis. Cytotoxic chemotherapy (chemo) is the standard of care. Recent data demonstrate that immunotherapy and anti-body drug conjugate based therapy can improve outcomes. Nevertheless survival remains poor. This SLR and MA was performed to assess the efficacy of current treatments for 2 nd line (2L) mTNBC.
Methods
EMBASE, MEDLINE, Cochrane databases were systematically searched from database inception to December 2018 for relevant studies of mTNBC with any systemic therapies in metastatic disease. Relevant congresses proceedings since 2016 and ClinicalTrials.gov were also searched. This SLR followed PRISMA guidelines with scope defined in terms of PICOS criteria (Population, Intervention, Comparators, Outcomes and Study design). Weighted averages (WA) for outcomes by treatment arm and line of therapy (LOT) were calculated. In addition, MA of overall response rate (ORR) among patients receiving single agent chemo (single chemo) as 2L and first line or later (1L+) was carried out using random-effects modeling for ORR.
Results
44 original studies were selected: 22 with 1L+, 7 with 2L, 15 with 2L or later (2L+). WAs of outcomes are presented in the Table. WAs of ORR for single chemo were less than ORR for combination chemo or chemo & biologics. No treatment showed consistently better survival over other treatments across all 3 groupings. MA of ORR in patients receiving single chemo as 2L and 1L+ were 11.9% (95% CI: 4.6, 20.8) and 15.6% (95% CI: 8.8-32.9), respectively. Table. Weighted Averages of Clinical Outcomes by Treatment and Line of Therapy.Table:
360P
Treatment | Line of Therapy | Overall Response Rate (%) | Progression Free Survival (median months) | Overall Survival (median months) |
---|---|---|---|---|
Single agent chemotherapy | 1L+ | 14.6 | 2.3 | 10.8 |
2L | 14.3 | 2.4 | 12.6 | |
2L+ | - | 3.1 | 12.3 | |
Combination chemotherapy | 1L+ | 29.7 | 4.4 | 10.5 |
2L | 31.0 | 4.1 | 10.0 | |
2L+ | - | 2.9 | 8.1 | |
Chemotherapy & Biologics | 1L+ | 22.6 | 2.9 | 10.6 |
2L | 35.8 | 5.6 | 17.9 | |
2L+ | 21.2 | 3.5 | 10.7 |
Conclusions
There is no clear standard of care in 2L TNBC. Response rates are low for single chemo and although response rates improve with combination therapies, no treatment regimen has demonstrated definitive improvement in outcomes. These results reinforce the need for new treatment strategies for mTNBC after 1L.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Purple Squirrel Economics.
Funding
Seattle Genetics, Inc.
Disclosure
P.A. Kaufman: Full / Part-time employment: Seattle Genetics, Inc. J. Feliciano: Full / Part-time employment: Seattle Genetics, Inc. P. Garfin: Full / Part-time employment: Seattle Genetics, Inc. L. Brown: Full / Part-time employment: Seattle Genetics, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract